The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

Bernstein, Çharles N.; Blanchard, James; Leslie, William D.; Wajda, André; Yu, Bo

doi:10.7326/0003-4819-133-10-200011210-00012

Cited by 430 publications

(260 citation statements)

References 17 publications

Supporting

Mentioning

238

Contrasting

Unclassified

Order By: Relevance

“…In a comprehensive systematic review of osteoporosis in IBD it is highlighted that the prevalence of severe demineralisation in patients with IBD depends on which evidence is considered; it has been reported to be as low as 2-16% (data from larger controlled studies) and as high as 18-42 % (from uncontrolled studies) (26) . The findings from four large population-based studies describing fracture risk in IBD have produced relatively similar results (27)(28)(29)(30) . While each of the studies has its limitations, the findings from these four studies collectively seem to suggest that patients with IBD may have increased fracture risk, but the magnitude of the excess risk is small and most evident in the elderly (5) .…”

Section: Risk Factors For Osteoporosissupporting

confidence: 53%

Altered bone metabolism in inflammatory disease: role for nutrition

Cashman

2008

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Osteoporosis is a major public health problem, and as life expectancy and the world's population continue to increase will become even more important. Thus, there is an urgent need to develop and implement nutritional approaches and policies for the prevention and treatment of osteoporosis. Patients with some chronic inflammatory diseases appear to be more likely to develop osteopenia, and in some cases earlier in life, which is of particular concern as the incidence of inflammatory diseases in the Western world is increasing. While the cause of bone loss in patients with inflammatory disease is multifactorial, nutrition may have a role. Many of these patients may have one or more nutritional deficiencies, which can lead to altered rates of bone metabolism. On the other hand, some nutritional factors may attenuate the inflammatory process itself, and thus may indirectly benefit bone metabolism and bone health in patients with inflammatory disease. The present review will consider these issues, particularly in the context of inflammatory bowel disease, coeliac diease and atherosclerosis.

show abstract

Section: Risk Factors For Osteoporosissupporting

confidence: 53%

Altered bone metabolism in inflammatory disease: role for nutrition

Cashman

2008

Proc. Nutr. Soc.

View full text Add to dashboard Cite

show abstract

“…Across a number of the autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, asthma, systemic lupus erythematous and IBD, studies suggest that vitamin D status may be associated with initiation, progression or severity of these diseases (1)(2)(3)(4)(5)(6) . In IBD, there is an established role for vitamin D in the prevention and treatment of osteoporosis, which is a known complication of this disease (7)(8)(9) . Indeed, there are clinical management guidelines for bone health (10) , for example, that recommend vitamin D and calcium…”

Section: Vitamin D and Immunomodulation: The Inflammatory Bowel Diseamentioning

confidence: 99%

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

There is increasing scientific interest in the field of vitamin D research, moving the focus beyond bone health to other disease processes. Low circulating vitamin D levels have been reported as a risk factor for several pathophysiologically divergent diseases, including cancers, diabetes, CVD, multiple sclerosis and inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). But, therein, remains the challenge: can any single nutrient contribute to multiple complex disease mechanisms and, ultimately, have therapeutic potential? The aim of this review is to critically evaluate several strands of scientific evidence surrounding vitamin D and inflammation, primarily focusing on IBD. Epidemiological studies suggest an increased incidence of IBD and rheumatoid arthritis in countries of more northern latitudes, mirroring sunlight patterns. A considerable body of evidence supports the anti-inflammatory effects of vitamin D, at least in animal models of IBD. Although it is accepted that suboptimal vitamin D status is common in IBD, some studies suggest that this associates with more severe disease. With regard to treatment, the data are only beginning to emerge from randomised controlled trials to suggest that people with IBD may remain in remission longer when treated with oral vitamin D. In conclusion, several strands of evidence suggest that vitamin D may modify the immune response in IBD. There is a continued need for large well-designed clinical trials and mechanistic studies to determine if, and how, this emerging promise translates into tangible clinical benefits for people with chronic debilitating diseases such as IBD.

show abstract

“…An analysis involving 6,027 Canadian patients with inflammatory bowel diseases showed a 40% increase in the risk of bone fractures compared to the general population [7]. An interesting study was conducted in the Netherlands, where an assessment of the incidence of bone fracture in patients with inflammatory bowel diseases examined about 231,000 cases of fracture.…”

Section: Non-specific Inflammatory Bowel Diseases and Osteoporosismentioning

confidence: 99%

Osteoporosis in Gastrointestinal Diseases

Krela‐Kaźmierczak¹,

Szymczak²,

Łykowska‐Szuber³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Secondary osteoporosis occurs as an isolated pathology or co-exists with types I and II osteoporosis. The gastroenterologist may come across osteoporosis or osteopenia in a patient with a gastrointestinal disease. This is often a young patient in whom investigations should be carried out and appropriate treatment initiated, aimed at preventing bone fractures and the formation of the best peak bone mass. Osteoporosis occurs in patients with the following conditions: Crohn's disease, ulcerative colitis, celiac disease, post gastrectomy patients, patients with short bowel syndrome, chronic hepatitis and cirrhosis, treated with steroids (steroid-induced osteoporosis) and patients using proton pump inhibitors chronically (state of achlorhydria). It is therefore necessary to approve a list of risk factors of secondary osteoporosis, the presence of which would be an indication for screening for osteoporosis, including a DXA study and the development of a separate algorithm for the therapeutic management of secondary osteoporosis accompanying gastrointestinal diseases, especially in premenopausal young women and young men, because there are currently no registered drugs with proven antifracture activity for this group of patients (Adv Clin Exp Med 2016, 25, 1, 185-190).

show abstract

The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

Abstract: The incidence of fracture among persons with inflammatory bowel disease is 40% greater than that in the general population.

Cited by 430 publications

References 17 publications

Altered bone metabolism in inflammatory disease: role for nutrition

Altered bone metabolism in inflammatory disease: role for nutrition

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

Osteoporosis in Gastrointestinal Diseases

Contact Info

Product

Resources

About